Hem › Fokal segmentell glomeruloskleros › North Carolina
Kliniska studier för Fokal segmentell glomeruloskleros i North Carolina
9 studier för Fokal segmentell glomeruloskleros söker deltagare vid platser i North Carolina.
Städer i North Carolina
Officiell studietext (engelska)
A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
- Investigator Site #16, New Bern
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 1 okt. 2026 · NCT07268638A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
- Duke University Medical Center, Durham
- Carolina Kidney Associates, Greensboro
- Cardinal Clinical Research, LLC - Shelby, Shelby
RekryterarFas 3
Ålder 12 och äldre · Alla kön · Uppdaterad 30 sep. 2026 · NCT07220083A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
- UNC Kidney Center- Site Number : 8400021, Chapel Hill
RekryterarFas 2
Ålder 16 till 75 · Alla kön · Uppdaterad 23 sep. 2026 · NCT06500702Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System
- University of North Carolina, Chapel Hill
Rekryterar
Upp till ålder 75 · Alla kön · Uppdaterad 28 aug. 2026 · NCT04065438Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- University of North Carolina, Chapel Hill
Rekryterar
Upp till ålder 21 · Alla kön · Uppdaterad 28 aug. 2026 · NCT02235857Nephrotic Syndrome Study Network
- University of North Carolina at Chapel Hill, Chapel Hill
- Atrium Health Levine Children's Hospital, Charlotte
RekryterarObservationsstudie
Upp till ålder 80 · Alla kön · Uppdaterad 10 juni 2026 · NCT01209000NEPTUNE Match Study
- University of North Carolina Chapel Hill, Chapel Hill
Rekryterar
Ålder 1 till 80 · Alla kön · Uppdaterad 10 juni 2026 · NCT04571658Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
- University of North Carolina at Chapel Hill, Chapel Hill
- Duke Molecular Physiology Institute, Durham
RekryterarFas 2
Ålder 1 till 17 · Alla kön · Uppdaterad 12 maj 2026 · NCT05003986A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
- University of North Carolina, Chapel Hill
- Atrium Health, Charlotte
RekryterarFas 3
Ålder 12 till 80 · Alla kön · Uppdaterad 3 feb. 2026 · NCT05183646Från ClinicalTrials.gov, data hämtad 5 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.